Soyoung Kim

List of Publications by Year
in descending order

47
papers

769
citations

567281
15
h-index

552781
26
g-index

48
all docs

48
docs citations

48
times ranked

1242
citing authors

#	ARTICLE	IF	CITATIONS
1	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	1.4	85
2	Dietary biomarker evaluation in a controlled feeding study in women from the Women's Health Initiative cohort ,. American Journal of Clinical Nutrition, 2017, 105, 466-475.	4.7	80
3	Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	5.2	48
4	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265.	2.4	47
5	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer, 2018, 124, 816-825.	4.1	44
6	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 1771-1779.	5.8	41
7	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury—Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	5.9	40
8	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
9	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 2020, 4, 983-992.	5.2	34
10	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
11	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Advances, 2020, 4, 5562-5573.	5.2	28
12	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Advances, 2022, 6, 486-494.	5.2	25
13	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
14	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplantation, 2019, 54, 1354-1360.	2.4	19
15	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2022, 28, 48.e1-48.e10.	1.2	18
16	Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. Journal of Allergy and Clinical Immunology, 2022, 149, 1097-1104.e2.	2.9	16
17	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i>−̃ MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
18	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances, 2018, 2, 1022-1031.	5.2	13

#	Article	IF	Citations
19	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Advances, 2019, 3, 2525-2536.	5.2	13
20	Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐*versus*‐host disease prophylaxis and haploidentical stem cell transplantation. British Journal of Haematology, 2021, 194, 145-157.	2.5	12
21	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
22	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica, 2023, 108, 150-160.	3.5	10
23	Group and within-group variable selection for competing risks data. Lifetime Data Analysis, 2018, 24, 407-424.	0.9	9
24	Combining biomarkers for classification with covariate adjustment. Statistics in Medicine, 2017, 36, 2347-2362.	1.6	8
25	Analysis of Multiple Survival Events in Generalized Case-Cohort Designs. Biometrics, 2018, 74, 1250-1260.	1.4	8
26	Statistical Methods for Time-Dependent Variables in Hematopoietic Cell Transplantation Studies. Transplantation and Cellular Therapy, 2021, 27, 125-132.	1.2	8
27	Stratified proportional subdistribution hazards model with covariate‐adjusted censoring weight for case‐cohort studies. Scandinavian Journal of Statistics, 2020, 47, 1222-1242.	1.4	7
28	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplantation and Cellular Therapy, 2021, 28, 101.e1-101.e1.	1.2	7
29	Improving the efficiency of estimation in the additive hazards model for stratified case–cohort design with multiple diseases. Statistics in Medicine, 2016, 35, 282-293.	1.6	5
30	Variable selection with group structure in competing risks quantile regression. Statistics in Medicine, 2018, 37, 1577-1586.	1.6	4
31	Bi-level variable selection for case-cohort studies with group variables. Statistical Methods in Medical Research, 2019, 28, 3404-3414.	1.5	4
32	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4
33	Optimal treatment regimes for competing risk data using doubly robust outcome weighted learning with bi-level variable selection. Computational Statistics and Data Analysis, 2021, 158, 107167.	1.2	4
34	Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. Biology of Blood and Marrow Transplantation, 2020, 26, S12.	2.0	3
35	Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR. Blood, 2021, 138, 912-912.	1.4	3
36	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined <scp>CIBMTR</scp>/<scp>CMWP</scp> of <scp>EBMT</scp> analysis. British Journal of Haematology, 2022, 198, 785-789.	2.5	2

#	Article	IF	Citations
37	Screening group variables in the proportional hazards model. Statistics and Probability Letters, 2018, 135, 20-25.	0.7	1
38	Case-cohort design in hematopoietic cell transplant studies. Bone Marrow Transplantation, 2021, , .	2.4	1
39	Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis. Blood, 2020, 136, 43-44.	1.4	1
40	Competing risks regression models with covariates-adjusted censoring weight under the generalized case-cohort design. Lifetime Data Analysis, 2022, 28, 241-262.	0.9	1
41	668. Clinical Spectrum of Powassan Virus Infection in Patients Presenting with Suspected Acute Tick-Borne Illness From a Lyme-Endemic Focus in the Midwest. Open Forum Infectious Diseases, 2018, 5, S241-S242.	0.9	0
42	Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes. Blood, 2016, 128, 70-70.	1.4	0
43	Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2018, 132, 252-252.	1.4	0
44	The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study. Blood, 2021, 138, 2894-2894.	1.4	0
45	The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2021, 138, 417-417.	1.4	0
46	Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity. Blood, 2020, 136, 36-37.	1.4	0
47	A calibrated Bayesian method for the stratified proportional hazards model with missing covariates. Lifetime Data Analysis, 2022, 28, 169.	0.9	0